Weiss Ratings Reiterates “Sell (E+)” Rating for 180 Life Sciences (NASDAQ:ATNF)

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating reissued by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

180 Life Sciences Price Performance

ATNF opened at $0.99 on Wednesday. The firm has a 50-day simple moving average of $0.99 and a two-hundred day simple moving average of $1.35. 180 Life Sciences has a 52 week low of $0.66 and a 52 week high of $17.75.

180 Life Sciences (NASDAQ:ATNF) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.67) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in 180 Life Sciences stock. Anson Funds Management LP acquired a new stake in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 225,271 shares of the company’s stock, valued at approximately $410,000. Anson Funds Management LP owned about 7.08% of 180 Life Sciences as of its most recent SEC filing. Institutional investors and hedge funds own 4.07% of the company’s stock.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.